CN116171283A - Glp-1受体拮抗剂 - Google Patents

Glp-1受体拮抗剂 Download PDF

Info

Publication number
CN116171283A
CN116171283A CN202180053052.3A CN202180053052A CN116171283A CN 116171283 A CN116171283 A CN 116171283A CN 202180053052 A CN202180053052 A CN 202180053052A CN 116171283 A CN116171283 A CN 116171283A
Authority
CN
China
Prior art keywords
compound
syndrome
group
ser
lysr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053052.3A
Other languages
English (en)
Chinese (zh)
Inventor
贾尔斯·阿尔贝特·布朗
迈尔斯·斯图尔特·康格里夫
康纳·斯库利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hepares Treatment Co ltd
Original Assignee
Hepares Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hepares Treatment Co ltd filed Critical Hepares Treatment Co ltd
Publication of CN116171283A publication Critical patent/CN116171283A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180053052.3A 2020-07-27 2021-07-27 Glp-1受体拮抗剂 Pending CN116171283A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2011604.2 2020-07-27
GBGB2011604.2A GB202011604D0 (en) 2020-07-27 2020-07-27 GLP-1 receptor antagonists
PCT/GB2021/051921 WO2022023723A1 (en) 2020-07-27 2021-07-27 Glp-1 receptor antagonists

Publications (1)

Publication Number Publication Date
CN116171283A true CN116171283A (zh) 2023-05-26

Family

ID=72339360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053052.3A Pending CN116171283A (zh) 2020-07-27 2021-07-27 Glp-1受体拮抗剂

Country Status (8)

Country Link
US (1) US20230279053A1 (https=)
EP (1) EP4188409A1 (https=)
JP (1) JP2023535476A (https=)
CN (1) CN116171283A (https=)
AU (1) AU2021319051A1 (https=)
CA (1) CA3190422A1 (https=)
GB (1) GB202011604D0 (https=)
WO (1) WO2022023723A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020074927A2 (en) * 2018-10-12 2020-04-16 Heptares Therapeutics Limited Glp-1 receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020074927A2 (en) * 2018-10-12 2020-04-16 Heptares Therapeutics Limited Glp-1 receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUNICE N.MURAGE 等: "Development of Potent Glucagon-like Peptide-1 Agonists with High Enzyme Stability via Introduction of Multiple Lactam Bridges", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 17, 5 August 2010 (2010-08-05), pages 6413 *
JOHN S DAVIES: "The cyclization of peptides and depsipeptides", J PEPT SCI, vol. 9, no. 8, 1 January 2003 (2003-01-01), pages 474 *

Also Published As

Publication number Publication date
GB202011604D0 (en) 2020-09-09
US20230279053A1 (en) 2023-09-07
CA3190422A1 (en) 2022-02-03
EP4188409A1 (en) 2023-06-07
WO2022023723A1 (en) 2022-02-03
AU2021319051A1 (en) 2023-03-16
JP2023535476A (ja) 2023-08-17

Similar Documents

Publication Publication Date Title
JP7634531B2 (ja) ｇＩＰおよびＧＬＰ－１デュアルアゴニストポリペプチド化合物、薬学的に許容できる塩、および使用
CN112409460B (zh) 一类glp-1/胰高血糖素受体双重激动剂及其应用
US20250368709A1 (en) Glp-1 receptor antagonists
AU2015225945B2 (en) Peptides hormone analogues derivable from preproglucagon
JP2006501820A (ja) 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
EP2895506A1 (en) Peptide analogues of glucagon and glp1
WO2024149080A1 (zh) 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
CN116171283A (zh) Glp-1受体拮抗剂
JP7812338B2 (ja) Ｇｌｐ受容体アゴニスト
CN113195517A (zh) 作为选择性生长抑素sst5受体激动剂的环己肽
CN115666623A (zh) 口服glp受体激动剂
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
RU2838225C1 (ru) Агонисты рецепторов glp
WO2026073030A1 (en) Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Britain

Address after: Britain

Applicant after: Nexla Pharmaceuticals UK Ltd.

Address before: Cambridge County, England

Applicant before: Hepares Treatment Co.,Ltd.

Country or region before: Britain